{"product_id":"ctla4-nfat-reporter-lentivirus-bhv19400277","title":"CTLA4\/NFAT Reporter Lentivirus","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc ul{margin:0 0 12px 22px}.bhp-desc li{margin:0 0 6px}\u003c\/style\u003e\n\u003ch2\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eCTLA-4 (CD152) is a co-inhibitory receptor and a central regulator of immune checkpoint control. Expressed on activated T cells and constitutively on regulatory T cells, it competes with the co-stimulatory receptor CD28 for the shared B7 ligands CD80 and CD86 on antigen-presenting cells, and binds them with higher affinity. By outcompeting CD28 and removing B7 ligands from the cell surface, CTLA-4 dampens T cell activation, reduces calcium-driven NFAT signaling, and enforces peripheral tolerance. Because CTLA-4 restrains anti-tumor immunity, blocking antibodies are a foundational cancer immunotherapy, and NFAT reporters provide a quantitative readout of CTLA-4-mediated suppression and its reversal.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eProduct Description \u0026amp; Applications\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThe CTLA4\/NFAT Reporter Lentivirus is an all-in-one immunotherapy reporter system for studying CTLA-4-mediated checkpoint signaling in T cells. The construct constitutively expresses the human CTLA-4 receptor; engagement of B7 ligands suppresses T cell activity, lowering cytosolic calcium, reducing NFAT activation, and decreasing dual reporter output of secreted Gaussia luciferase and a fluorescent protein (GFP or RFP). Anti-CTLA-4 antibodies that block receptor engagement restore reporter activity.\u003c\/p\u003e\n\u003cp\u003eTransducing target cells with the high-titer lentivirus establishes a stable, pathway-specific reporter cell line. Applications include studying immune checkpoint suppression and testing checkpoint-blockade agents. Supplied as third-generation, VSV-G-pseudotyped particles purified by PEG precipitation and sucrose gradient centrifugation, effective in primary and thawed cells.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eAbout This Product\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThis 2-vial immunotherapy reporter system consists of a \u003cstrong\u003eVial 1 Receptor Lentivirus\u003c\/strong\u003e encoding human CTLA4 under a constitutive promoter with antibiotic selection, and a \u003cstrong\u003eVial 2 Reporter Lentivirus\u003c\/strong\u003e encoding tandem NFAT (or NF-κB) response elements driving a dual reporter (GFP, GFP-P2A-GLuc, GLuc, GLuc-P2A-GFP, GLuc-P2A-RFP, RFP, RFP-P2A-GLuc). Sequential transduction and selection generates a dual-stable effector cell line that responds quantitatively to receptor stimulation with a ratiometric fluorescent + bioluminescent readout.\u003c\/p\u003e\n\u003cp\u003eSecreted Gaussia luciferase (where included) accumulates in conditioned media, enabling kinetic sampling without cell lysis. The combined fluorescent and luminescent outputs allow parallel microscopy-based visualization and plate-reader luminometry from the same cell population — providing assay redundancy and flexibility for potency testing formats compliant with regulatory expectations for cell-based functional assays.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"LipExoGen Biotech","offers":[{"title":"GLuc-P2A-GFP \/ Blasticidin \/ 2x10^6","offer_id":53251616113005,"sku":"TRV-0029-6S","price":895.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/Vector-Layout-1024x261_112d1832-d98f-436e-99de-345e734a41ce.jpg?v=1782157779","url":"https:\/\/www.ebiohippo.com\/products\/ctla4-nfat-reporter-lentivirus-bhv19400277","provider":"BioHippo","version":"1.0","type":"link"}